M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…
McAlinden Research PartnersAugust 9, 2022
Psychedelic medicine, focused on alternative mental health therapies that utilize drugs like LSD, MDMA and psilocybin, is becoming increasingly popular…
McAlinden Research PartnersJuly 18, 2022
Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…
McAlinden Research PartnersJuly 14, 2022
A decade after its discovery, an authorization of CRISPR drugs to be marketed in the US may only be a…
McAlinden Research PartnersJuly 11, 2022
Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…
McAlinden Research PartnersJune 14, 2022
Despite a prolonged sell-off in biotech stocks, the development of genomic medicine has continued apace. For just the third time,…
McAlinden Research PartnersMay 23, 2022
The acquisition of biotechnology firms is one of the most common ways big pharma replenishes their pipeline of new drugs. However,…
McAlinden Research PartnersMay 12, 2022
Digital health continues to garner significant investor interest as startups across the industry raked in a record-breaking $29.1 billion last…
McAlinden Research PartnersJanuary 18, 2022
The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…
McAlinden Research PartnersJanuary 4, 2022
